📢NEXT WEEK📢Prophylactic #peritoneal Management of High-Risk #ColonCancer
🗓️3 NOV-18.30 CEST
🗣Dr @AndreasBrandl8, Dr @alarjosan, Dr Diane Goéré & Dr Pieter Tanis ➡️https://lnkd.in/gNsACYN
#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer @CombatCancer
They don’t do an emoji for HIPEC with agitation bubbles of CO2.
Is this close enough @alarjosan?
🛁🛁🛁🛁🛁
Laparoscopic cytoreductive surgery and HIPEC for a limited low-grade pseudomyxoma peritonei.
Performed by Dr @alarjosan and team at @HUReinaSofia
👏🏻👏🏻👏🏻👏🏻
📢Webinar Alert📢
Prophylactic #peritoneal Management of High-Risk #ColonCancer
🗓️3 November-18.30 CEST
🗣Dr @AndreasBrandl8, Dr Alvaro-Arjona-Sanchez, Dr Diane Goéré & Dr Pieter Tanis
👉https://www.essoweb.org/courses/
#HIPEC #PeritonealMetastases #colorectalsurgery #colorectalcancer
Three of our portfolio companies (@CombatCancer @LightpointMed
and @entiahealth) named by Coutts as "#medtech marvels supporting the NHS"
Coutts backs med-tech marvels supporting NHS
Meet four of the firms forging the future of health care with help from our clients
www.coutts.com
To register for this Friday's webinar (5-6 UK) click on the Eventbrite link
#HIVEC #BCGUnresponsive
HIVEC for BCG Unresponsive
Find out more about HIVEC in BCG Unresponsive Patients with Clinical Discussion and Live Q&A. EAU20 Presented Data.
www.eventbrite.co.uk
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
@cordekroon @HUReinaSofia @ESSOnews @operarelcancer @SWexner @DeliaCortesGuir @FarazKh65499316 @dr_mohammadyami @AndreasBrandl8 @annafagottimd Closed system with CO2 agitation system @CombatCancer @jansenaxel is an option for drug distribution
Join us on Friday 4th September at 5pm to find out more about HIVEC in BCG Unresponsive patients
#HIVEC #EAU20 Data presented at EAU20 shows HIVEC treated BCG unresponsive patients 54% RFS at 24 months. Complete Response Rate for BCG unresponsive CIS patients over 70% at 6 months. Contact us to find out more.
Just in case you missed this trial data presented at AUA20, #HIVEC immediately prior to TURBT shows equivalent recurrence to I-POP but with 100% adherence for HIVEC, 33% greater than for I-POP.https://bit.ly/3fjnHyD
https://laparoscopic-hipec-a-new-point-of-view.eventbrite.co.uk
@CombatCancer #HIPEC Don't forget to register to join Combat and Dr Alvaro-Arjona-Sanchez later today to find out more.
https://www.urotoday.com/conference-highlights/aua-2020/aua-2020-bladder-cancer/122466-aua-2020-bcg-vs-chemohyperthermia-with-mitomycin-c-for-high-risk-non-muscle-invasive-bladder-carcinoma-preliminary-results-of-hivec-hr-randomized-clinical-trial.html via @urotoday
Many thanks @urotoday for covering our trial data https://twitter.com/urotoday/status/1276923364402225152
#BCG vs chemohyperthermia with mitomycin C for high-risk #NMIBC. Preliminary results of HIVEC-HR randomized clinical trial presented by @DrFelixGuerrero @Urologia12. #AUAlive written coverage by @zklaassen_md @GACancerCenter on UroToday > https://bit.ly/384fw6I @AmerUrological
#HIPEC #Laparoscopic #SurgicalOncology @CombatCancer Join Combat and Consultant Surgeon Dr Alvaro-Arjona-Sanchez to find out more about Laparoscopic HIPEC experience and results. Register for online event https://laparoscopic-hipec-a-new-point-of-view.eventbrite.co.uk
Combat is proud to be sponsoring the Global Congress on Bladder Cancer on the 20th and 21st of September 2018 in Madrid. More Clinical data on HIVEC treatments will be presented during the meeting. For more information see click here or visit us on stand.
